FrancophonIA/ELRC3.0 huggingface dataset:
English: The Committee noted that there is a plausible mechanism for how these medicines may cause fibrosis, through activation of ‘5-HT2B receptors', leading to cell division and formation of fibrous tissue, although other mechanisms might be involved.
Latvian: Komiteja nor d ja, ka noskaidrots ticams fibrozes veidošan s meh nisms šo z u ietekm , proti, aktiv joties 5-HT2B receptoriem, tiek izrais ta š nu dal šan s un fibrozes audu veidošan s, tom r iesp jami ar citi meh nismi.
English: The CHMP also recommended that companies that make these two medicines should conduct studies to look at how closely doctors follow the updated prescribing information and the impact that these changes have on the incidence of fibrosis of the heart valves.
Latvian: CHMP ar ieteica šo divu z u ražot jiem veikt p t jumus, lai noskaidrotu, k rsti iev ro atjaunotaj z u dokument cij iek autos nor d jumus un k šie groz jumi ietekm sirds v rstu u fibrozes att st bas biežumu.
English: • Patients or their carers who have any questions or concerns should speak to their doctor or pharmacist.
Latvian: • Neskaidr bu gad jum pacientiem vai vi u apr p t jiem j v ršas pie rsta vai farmaceita.
English: This review was carried out under an ‘Article 31' referral1.
Latvian: Šo v rt šanu veica saska ar 31. panta v rt jumproced ru
English: Ergot-derived dopamine agonists are a group of medicines consisting of bromocriptine, cabergoline, dihydroergocryptine, lisuride and pergolide.
Latvian: No melno graudu alkalo diem atvasin ti dopam na agonisti ir z u grupa, kuras sast v no bromokript na, kabergol na, dihidroergokript na, lizur da un pergol da.
English: In contrast, there is not enough evidence to determine whether there is an increased risk of fibrosis of the heart valves in patients taking bromocriptine, dihydroergocryptine or lisuride.
Latvian: Turpretim nav pietiekamu pier d jumu par to, vai bromokript na, dihidroergokript na un lizur da lietošanas gad jum ir palielin ts sirds v rstu u fibrozes risks.
English: Fibrosis can affect a number of body structures such as the heart, the lungs or the abdomen.
Latvian: Fibroze var skart vair kus org nus, piem ram, sirdi, plaušas vai v dera dobuma org nus.
English: This group of dopamine agonists are called ‘ergotderived', because they were first produced from a type of fungus called ergot.
Latvian: S kotn ji no melno graudu alkalo diem atvasin tus dopam na agonistus ieguva no s nes, ko sauc par melnajiem graudiem.
English: • a reduction of the maximum recommended dose to 3 mg per day;
Latvian: • maksim l ieteicam deva j mazina l dz 3 mg dien ;
English: They are also used to treat conditions including hyperprolactinaemia (high levels of the hormone prolactin in the blood) and prolactinoma (a non-cancerous tumour of the pituitary gland at the base of the brain), and to prevent lactation (production of breast milk) and migraine.
Latvian: No melno graudu alkalo diem atvasin tus dopam na agonistus lieto ar hiperprolaktin mijas (augsta hormona prolakt na l me a asin s) un prolaktinomas (labdab ga hipof zes audz ja) rst šanai, k ar lai nov rstu lakt ciju (m tes piena veidošanos) un migr nu.
English: However, two studies published in scientific journals using echocardiography (ultrasound scans of the heart) have shown that fibrosis of the heart valves can begin to develop well before symptoms start to appear.
Latvian: Tom r dati no diviem zin tniskos žurn los public tiem p t jumiem, kuros izmantota sirds ultraska as izmekl šana jeb ehokardiogr fija, liecina, ka sirds v rstu u fibroze var s kties pirms simptomu rašan s. Tas nor da uz to, ka kardi l fibroze var tu b t biež ka blakuspar d ba nek uzskat ts iepriekš.
English: For cabergoline and pergolide, the Committee noted that the risk of fibrosis of the heart valves is well established, that the prescribing information for both products already includes contraindications stating that patients with evidence of heart valve problems should not take them, and that the medicines should only be used for Parkinson's disease in patients who have already taken or cannot take other treatments.
Latvian: Komiteja nor d ja, ka kabergol na un pergol da dokument cij sirds v rstu u fibrozes risks ir labi atspogu ots un dokument cij jau noteikts, ka z les kontrindic tas pacientiem, kuriem konstat ta sirds v rstu u kaite.
English: The CHMP reviewed all of the available information on the risk of fibrosis and valve problems from clinical trials, observational studies (studies looking at the effects of medicines as they are used by patients) and ‘spontaneous reports' of side effects made by patients or doctors to the companies that make the medicines or to health authorities.
Latvian: CHMP v rt ja visus kl niskos p t jumos un z u lietošanas nov rojumos (p t jumos, kuros tiek p t ta pacientu lietoto z u ietekme) ieg tos datus par fibrozes risku un v rstu u darb bas trauc jumiem, k ar pacientu un rstu spont nos zi ojumus par blakuspar d b m z u ražot jiem un atbild g m vesel bas apr pes iest d m.
English: Based on the information available, the CHMP has concluded that the marketing authorisations for the ergot-derived dopamine agonists should be maintained, but changes to the prescribing information for the medicines should be introduced to reduce the risk of fibrosis.
Latvian: Balstoties uz pieejamo inform ciju, CHMP secin ja, ka no melno graudu alkalo diem atvasin tu dopam na agonistu re istr cijas apliec bas darb ba j saglab , tom r fibrozes riska mazin šanai z u dokument cij j ievieš groz jumi.
English: The review focused on the risk of fibrosis (the formation of fibrous tissue in some body structures) in patients taking these medicines for long periods, particularly cardiac fibrosis (abnormal thickening of the heart valves).
Latvian: V rt šanas m r is bija noskaidrot fibrozes (saistaudu vairošan s noteiktos org nos), paši kardi las fibrozes (patolo iskas sirds v rstu u sabiezin šan s) riska pacientiem, kuri š s z les lieto ilgstoši.
English: In addition, the CHMP recommended that a contraindication for patients with pre-existing valve problems should be included in the prescribing information for bromocriptine and dihydroergocryptine-containing medicines.
Latvian: Papildus CHMP ieteikusi bromokript na un dihidroergokript na saturošo z u dokument cij iek aut nosac jumu, ka šo prepar tu lietošana kontrindic ta tiem pacientiem, kuriem jau konstat ti sirds v rstu u darb bas trauc jumi.
English: However, since such a risk cannot completely be excluded, the Committee recommended that warnings on the possible risk of fibrosis in patients taking these medicines at high doses for long periods should be included in their prescribing information.
Latvian: Tom r, t k šo risku nevar piln b izsl gt, Komiteja ieteica z u dokument cij iek aut br din jumu par iesp jamu fibrozes risku pacientiem, kas ilgstoši lieto lielu šo z u devu.
English: • a warning stating that patients must be monitored for signs of fibrosis with echocardiography before treatment is started and regularly during treatment;
Latvian: • br din jums par to, ka pacientiem pirms terapijas un regul ri t s laik j veic ehokardiogr fija, lai p rliecin tos, vai nerodas fibrozes paz mes;
English: Dopamine agonists work by stimulating brain and nerve cells in a similar way to dopamine, a messenger substance in the nervous system.
Latvian: Dopam na agonisti stimul smadze u un nervu š nas l dz gi nervu sist mas inform cijas nes jvielai dopam nam.
English: • Doctors should prescribe ergot-derived dopamine agonists according to the updated prescribing information.
Latvian: • rstiem j paraksta no melno graudu alkalo diem atvasin ti dopam na agonisti saska ar atjaunoto z u dokument ciju.
English: They have been available on the market for many years and are mainly used to treat Parkinson's disease, either on their own or in combination with other medicines.
Latvian: Šie prepar ti pieejami jau daudzus gadus, un tos monoterapij vai kombin cij ar cit m z l m lieto galvenok rt Parkinsona slim bas rst šanai.
English: The European Medicines Agency (EMEA) has completed a review of the safety of the ergot-derived dopamine agonists, a group of medicines that are mainly used to treat Parkinson's disease.
Latvian: Eiropas Z u a ent ra (EMEA) pabeigusi v rt t no melno graudu alkalo diem atvasin tu dopam na agonistu nekait gumu.
English: Therefore, the CHMP recommended that the prescribing information for these two medicines should be updated to include:
Latvian: T p c CHMP ieteica min to z u dokument ciju atjaunin t, iek aujot taj š du inform ciju:
English: QUESTIONS AND ANSWERS ON THE REVIEW OF ERGOT-DERIVED DOPAMINE AGONISTS
Latvian: JAUT JUMI UN ATBILDES PAR V RT ŠANU, KAS VEIKTA SAIST B AR DOPAM NA AGONISTIEM, KURI ATVASIN TI NO MELNO GRAUDU ALKALO DIEM
English: Consequently, the United Kingdom's medicines regulatory authority asked the CHMP to review the risk of fibrosis, including cardiac fibrosis, associated with the use of ergot-derived dopamine agonists.
Latvian: T p c Apvienot s Karalistes z u apstiprin šanas regul još iest de a ent ra l dza CHMP v rt t fibrozes (ar kardi las fibrozes) risku no melno graudu alkalo diem atvasin tu dopam na agonistu lietošanas gad jum .
English: --1 ≥ 394AU/ml (Antigenic units determined by ELISA) (1400 AU corresponding to ≥ 492 AU in the potency test)
Latvian: --1 ≥ 394AV/ml (Antigēna vienības, kas noteiktas ar ELISA) (1400 AV atbilst ≥ 492 AV potences testā)
English: Vial (type I glass) closed with a rubber stopper secured with aluminium cap
Latvian: Flakons (I tipa stikla) noslēgts ar gumijas aizbāzni un aizvākots ar alumīnija vāciņu
English: 10 vials Zero days
Latvian: 10 flakoni
English: Packaging Content Package size
Latvian: Iepakojuma veids
English: Invented name
Latvian: Piešķirtais nosaukum s
English: It was to be available as 10 mg tablets.
Latvian: Bija paredzēts, ka tas būs pieejams 10 mg tablešu veidā.
English: This complex then blocks mTOR.
Latvian: Šis komplekss bloķē mTOR.
English: 14 December 2012 EMA/807998/2012 EMEA/H/C/2259
Latvian: EMEA/H/C/2259
English: What is Jenzyl?
Latvian: Kas ir Jenzyl?
English: The main measure of effectiveness was the time patients lived until their disease got worse.
Latvian: Galvenais efektivitātes rādītājs bija laiks, ko pacienti nodzīvoja līdz slimības pasliktināšanās brīdim.
English: This is expected to slow down the growth and proliferation of cancer cells.
Latvian: Paredzams, ka tas palēninās vēža šūnu augšanu un vairošanos.
English: The study compared Jenzyl with placebo (a dummy treatment).
Latvian: Pētījumā Jenzyl salīdzināja ar placebo (neīstu ārstēšanas līdzekli).
English: The application was withdrawn after the CHMP had evaluated the documentation provided by the company and formulated a list of questions.
Latvian: Pieteikums tika atsaukts pēc tam, kad CHMP bija novērtējusi uzņēmuma iesniegtos dokumentus un sagatavojusi jautājumu sarakstu.
English: Jenzyl is a medicine that contains the active substance ridaforolimus.
Latvian: Jenzyl ir zāles, kas satur aktīvo vielu ridaforolimu.
English: The summary of the opinion of the Committee for Orphan Medicinal Products for Jenzyl can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/Rare disease designation (soft tissue sarcoma and primary malignant bone tumours).
Latvian: Retu slimību ārstēšanai paredzēto zāļu komitejas atzinuma kopsavilkums par Jenzyl ir pieejams aģentūras tīmekļa vietnē: ema.europa.eu/Find medicine/Human medicines/Rare disease designation (mīksto audu sarkoma un primāri ļaundabīgi kaulu audzēji).
English: The CHMP considered this benefit to be modest, when taking into account that patients usually survived for a long time after their disease had progressed.
Latvian: CHMP uzskatīja, ka šis ieguvums ir mērens, ņemot vērā, ka pacienti pēc slimības progresēšanas parasti nodzīvoja vēl ilgi.
English: The company had not yet responded to the last round of questions at the time of the withdrawal.
Latvian: Pieteikuma atsaukšanas brīdī uzņēmums vēl nebija sniedzis atbildes uz pēdējā posma jautājumiem.
English: The company informed the CHMP that there are no consequences for patients currently included in clinical trials using Jenzyl.
Latvian: Uzņēmums informēja CHMP, ka tas nerada sekas pacientiem, kuri pašlaik piedalās Jenzyl klīniskajos pētījumos.
English: Since mTOR is involved in the control of cell division and the growth of blood vessels, ridaforolimus prevents the division of tumour cells and reduces their blood supply.
Latvian: Tā kā mTOR ir iesaistīts šūnu dalīšanās un asinsvadu augšanas kontroles procesā, ridaforolims novērš audzēja šūnu dalīšanos un mazina to apgādi ar asinīm.
English: Therefore, at the time of the withdrawal, the CHMP was of the opinion that the benefits of Jenzyl did not outweigh its risks.
Latvian: Tāpēc atsaukšanas brīdī CHMP uzskatīja, ka zāļu Jenzyl ieguvumi nepārsniedz to radīto risku.
English: Withdrawal of the marketing authorisation application for Jenzyl (ridaforolimus)
Latvian: Zāļu Jenzyl (ridaforolims) reģistrācijas apliecības pieteikuma atsaukšana
English: The CHMP also considered that the somewhat larger effect seen in patients who had received two or three previous regimens of chemotherapy compared with those who received one or more regimens might not reflect the medicine's true effect size, as the reason the medicine would work better at later stages of the disease was unclear.
Latvian: CHMP uzskatīja, ka nedaudz labāks rezultāts pacientiem, kuri iepriekš bija saņēmuši divas vai trīs ķīmijterapijas shēmas, salīdzinājumā ar tiem, kuri saņēmuši tikai vienu shēmu, var neatspoguļot zāļu patieso ietekmes lielumu, jo iemesls, kādēļ zāles slimības vēlīnās stadijās darbotos labāk, nebija skaidrs.
English: The CHMP was concerned that taking Jenzyl only led to a small increase in the time patients lived until their disease got worse compared with placebo (18 versus 15 weeks in patients who had one or more regimens of previous chemotherapy, and 16 versus 10 weeks in patients who had received two or three previous regimens of chemotherapy).
Latvian: CHMP izteica bažas, ka, lietojot tikai Jenzyl, laiks, ko pacienti nodzīvo līdz slimības pasliktināšanās brīdim, salīdzinot ar placebo lietošanu, palielinājās tikai nedaudz (18 nedēļas salīdzinājumā ar 15 nedēļām pacientiem, kuriem iepriekš lietota viena vai vairākas ķīmijterapijas shēmas, un 16 nedēļas salīdzinājumā ar 10 nedēļām pacientiem, kuri iepriekš bija saņēmuši divas vai trīs ķīmijterapijas shēmas).
English: It was expected to be used as maintenance therapy in patients who have already received two or three regimens of chemotherapy.
Latvian: To bija paredzēts lietot balstterapijai pacientiem, kuri iepriekš jau bija saņēmuši divas vai trīs ķīmijterapijas shēmas.
English: In its letter notifying the Agency of the withdrawal of application, the company stated that it decided to withdraw the application since the CHMP considered that the data provided did not allow the Committee to conclude on a positive benefit-risk balance.
Latvian: Vēstulē, kurā uzņēmums informēja Aģentūru, ka ir nolēmis atsaukt pieteikumu, bija norādīts, ka šāds lēmums pieņemts, jo CHMP uzskatīja, ka iesniegtie dati neļauj Komitejai izdarīt secinājumu, ka ieguvumu un riska attiecība ir pozitīva.
English: In the body, ridaforolimus first attaches to a protein called FKBP-12 that is found inside cells to make a ‘complex'.
Latvian: Organismā ridaforolims vispirms šūnās piesaistās pie olbaltumvielas FKBP-12, veidojot kompleksu.
English: In terms of safety, the CHMP was concerned by the high frequency of side effects interfering with the patient's wellbeing as well as some uncommon but potentially lifethreatening side effects.
Latvian: No drošuma viedokļa CHMP bija bažas par pacienta pašsajūtu ietekmējošo blakusparādību lielo sastopamību, kā arī par dažām retākām, bet iespējami dzīvībai bīstamām blakusparādībām.
English: Based on the review of the data and the company's response to the CHMP list of questions, at the time of the withdrawal, the CHMP had some concerns and was of the provisional opinion that Jenzyl could not have been approved for the treatment of patients with metastatic soft tissue sarcoma or bone sarcoma as maintenance therapy.
Latvian: Pamatojoties uz izskatītajiem datiem un uzņēmuma atbildēm uz CHMP jautājumu sarakstu, atsaukšanas brīdī CHMP bija daži iebildumi, un CHMP tobrīd atzina, ka Jenzyl nevarēja apstiprināt pacientu ar metastātisku mīksto audu sarkomu ārstēšanai vai balstterapijai pacientiem ar kaulu sarkomu.
English: What was Jenzyl expected to be used for?
Latvian: Kādam nolūkam bija paredzēts lietot Jenzyl?
English: Jenzyl was expected to be used for the treatment of adults with soft tissue sarcoma (a type of cancer that affects the soft, supporting tissues of the body) or bone sarcoma (bone cancer) that are metastatic (have spread to other parts of the body).
Latvian: Jenzyl bija paredzēts lietot, lai pieaugušajiem ārstētu mīksto audu sarkomu (vēža veids, kas skar ķermeņa mīkstos, balsta funkciju pildošos audus) vai metastātisku (uz citām ķermeņa daļām izplatījušos) kaulu sarkomu (kaulu vēzi).
English: Jenzyl was designated an ‘orphan medicine' (a medicine to be used in rare diseases) on 26 August 2005 and 28 October 2005 for the treatment of soft tissue sarcoma and primary malignant bone tumours.
Latvian: 2005. gada 26. augustā un 2005. gada 28. oktobrī Jenzyl apstiprināja kā zāles retu slimību ārstēšanai, lai ārstētu mīksto audu sarkomu un primārus ļaundabīgus kaulu audzējus.
English: The company presented the results of one main study involving 711 patients with metastatic soft tissue sarcoma or bone sarcoma who have received up to four cycles of one, two or three alternative chemotherapy regimens.
Latvian: Šajā pētījumā piedalījās 711 pacienti ar metastātisku mīksto audu sarkomu vai kaulu sarkomu, kuri iepriekš bija saņēmuši līdz četrām alternatīvas ķīmijterapijas shēmām.
English: On 27 November 2012, Merck Sharp & Dohme Limited officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a marketing authorisation for Jenzyl, for the maintenance treatment of patients with metastatic soft tissue sarcoma or bone sarcoma previously treated with chemotherapy.
Latvian: Uzņēmums Merck Sharp & Dohme Limited 2012. gada 27. novembrī oficiāli informēja Cilvēkiem paredzēto zāļu komiteju (CHMP) par savu lēmumu atsaukt zāļu Jenzyl reģistrācijas apliecības pieteikumu.
English: How is Jenzyl expected to work?
Latvian: Kāda ir paredzamā Jenzyl iedarbība?
English: The withdrawal letter is available here.
Latvian: Uzņēmuma vēstule, kurā tas informē aģentūru par pieteikuma atsaukšanu, ir atrodama šeit.
English: The active substance in Jenzyl, ridaforolimus, blocks the action of an enzyme called ‘mammalian target of rapamycin' (mTOR), which regulates the growth and division of cells in the body and which has increased activity in patients with sarcoma.
Latvian: Jenzyl aktīvā viela ridaforolims bloķē enzīma, ko dēvē par “rapamicīna zīdītāju mērķi”(mTOR), darbību.
English: 5 x 2 tablets
Latvian: 5 x 2 tabletes
English: Package sizes perforated unit dose blister (PVC/Alu)
Latvian: Iepakojuma lielums perforēts blisteris ar vienu devu kontūrligzdā (PVH/Al)
English: Medicinal Product no longer authorised
Latvian: Zāles vairs nav reğistrētas
English: Invented name Strength Pharmaceutical form Route of administration Packaging
Latvian: Stiprums Zāļu forma
English: Pack size
Latvian: numurs
English: MA (EU) number (Invented) name
Latvian: (Piešķirtais)
English: This difference was not statistically significant.
Latvian: Šī atšķirība nebija statistiski nozīmīga.
English: Therefore, these findings are considered to be incidental.
Latvian: Tāpēc šīs atrades uzskata par nejaušām.
English: Παπαλοΐζου Λτδ Λεωφ.
Latvian: Χρ.Γ. Παπαλοΐζου Λτδ Λεωφ.
English: A risk to the newborns/infants cannot be excluded.
Latvian: Nevar izslēgt risku jaundzimušajiem/ zīdaiņiem.
English: • if you have previously used this medicine or other similar preparations in a different concentration.
Latvian: • ja iepriekš esat lietojis šīs vai citas līdzīgas zāles citā koncentrācijā;
English: Av. D. João II,
Latvian: D. João II,
English: Very rare (<1/10,000) and not known (cannot be estimated from the available data)
Latvian: Ļoti reti (<1/10 000) un nav zināms (nevar noteikt pēc pieejamajiem datiem).
English: He may advise you to stop applying this medicine for a few days (i.e. to have a short rest from treatment).
Latvian: Viņš var ieteikt Jums uz pāris dienām pārtraukt šo zāļu lietošanu (t. i., nedaudz “atpūsties” no ārstēšanas).
English: Zyclara is for external use only.
Latvian: Zyclara paredzēts tikai ārīgai lietošanai.
English: Frequencies are defined as:
Latvian: Sastopamības biežums definēts šādi:
English: • Do not use more cream than your doctor has advised.
Latvian: • Nelietojiet vairāk krēma, kā ārsts norādījis.
English: Meda AB Pipers väg 2A 170 73 Solna Sweden
Latvian: Meda AB Pipers väg 2A 170 73 Solna Zviedrija
English: Do not use this medicine until your doctor has shown you the right way to use it.
Latvian: Nelietojiet šīs zāles, kamēr ārsts nav parādījis, kā tās pareizi lietojamas.
English: 61352 Bad Homburg Germany
Latvian: 61352 Bad Homburg
English: Studies in animals do not indicate direct or indirect harmful effects in pregnancy.
Latvian: Pētījumi ar dzīvniekiem neliecina par tiešu vai netiešu kaitīgu ietekmi grūtniecības laikā.
English: This medicine may reveal and treat actinic keratosis that have not be seen or felt before, and these may later go away.
Latvian: Šīs zāles var atklāt un ārstēt aktīnisko keratozi, kas pirms tam nav bijusi redzama vai sajūtama, un tā vēlāk var izzust.
English: Mylan Medical SAS 40-44 rue Washington 75008 Paris
Latvian: Mylan Medical SA 40-44 rue Washington 75008 Paris
English: Systemic reactions
Latvian: Sistēmiskas reakcijas
English: Your doctor will discuss the risks and benefits of using Zyclara during pregnancy.
Latvian: Jūsu ārsts pārrunās ar Jums riskus un priekšrocības, lietojot Zyclara grūtniecības laikā.
English: • Only use the cream externally (on the skin of face or scalp).
Latvian: • Lietojiet krēmu tikai ārīgi (uz sejas vai galvas matainās daļas ādas).
English: • Periodic Safety Update Reports
Latvian: • Periodiski atjaunojamais drošības ziņojums
English: The cream should not be applied more than once daily.
Latvian: Krēmu nedrīkst uzklāt vairāk kā vienu reizi dienā.
English: This medicine stimulates your body's own immune system to produce natural substances which help fight your actinic keratosis.
Latvian: Šīs zāles stimulē paša organisma imūnsistēmu izstrādāt dabiskas vielas, kas palīdz cīnīties ar aktīnisko keratozi.
English: This medicine should not be given to children below the age of 18 years because the safety and efficacy in patients below the age of 18 years have not been established.
Latvian: Šīs zāles nedrīkst dot bērniem līdz 18 gadu vecumam, jo lietošanas drošums un efektivitāte par 18 gadiem jaunākiem pacientiem nav noskaidrota.
English: - if you are allergic to imiquimod or any of the other ingredients of this medicine (listed in section 6).
Latvian: - ja Jums ir alerģija pret imihimodu vai kādu citu (6.punktā minēto) šo zāļu sastāvdaļu.
English: What Zyclara is and what it is used for
Latvian: Kas ir Zyclara un kādam nolūkam tās lieto
English: If there is pus or another sign of skin infection (frequency not known), discuss this with your doctor.
Latvian: Ja atklājat strutas vai kādu citu ādas infekcijas (biežums nav zināms) pazīmi, apspriediet to ar savu ārstu.
English: Many of the side effects of this medicine are due to its local action on your skin.
Latvian: Daudzas no šo zāļu blakusparādībām izraisa tā vietējā iedarbība uz Jūsu ādu.
English: These reactions can be a sign that the medicine is working as intended.
Latvian: Šīs reakcijas varētu būt zīme, ka zāles darbojas, kā paredzēts.
English: This might make you more susceptible to infections, make you bruise more easily or cause tiredness.
Latvian: Tas var padarīt Jūs jutīgākus pret infekcijām, vieglāk var rasties zilumi vai būt nogurums.
English: The efficacy of Zyclara was studied in two double-blind, randomized, vehicle-controlled clinical studies.
Latvian: Zyclara efektivitāte tika pētīta divos dubultmaskētos, randomizētos, ar nesējvielu kontrolētos klīniskos pētījumos.